<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05050344</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0343</org_study_id>
    <nct_id>NCT05050344</nct_id>
  </id_info>
  <brief_title>Moya Moya Syndrome With or Withtout Sickle Cell Disease</brief_title>
  <acronym>BMM-ScD</acronym>
  <official_title>Descriptive Bicentric Study of Moya Moya Syndrome and Disease in Sickle Cell Disease Patients and Not Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Moya Moya disease or syndrome ar characterized by a progressive or occlusion of the&#xD;
      intracranial carotid arteries and their mainproximal branches, followed by the development of&#xD;
      fragile neovessels at the base of the skull, leding to a high risk of both ischemic and&#xD;
      hemorragic stroke over time. Moya Moya syndrome are associated to a variety of disease, which&#xD;
      main frequent is sickle cell disease (SCD).&#xD;
&#xD;
      Among patients with SCD who had suffered from at least one ischemic stroke, the prevalence of&#xD;
      moya moya syndrome was estimated up to 43%. In general, therapeutic strategies in Moya Moya&#xD;
      to prevent first ever ou recurrent stroke can be divided into conservative medical treatment&#xD;
      and surgical revascularisation (direct bypass, indirect bypass or combined bypass).&#xD;
&#xD;
      The aim of this study is to compare prognosis of patients with Moya Moya syndrome associated&#xD;
      with sickle cell disease or not. The investigators retrospectiveluy analysed medical chart&#xD;
      from 2010 to 2021 of patients with Moya Moya disease or syndrome at two French university&#xD;
      hospitals (including a center of the french West Indies where prevalence of sickle cell&#xD;
      disease is high). The diagnosis was based on angiography or MRI records showing uni- or&#xD;
      bilateral stenosis of distal intracranial internal carotide arteries or middle cerebral&#xD;
      arteries associated wirh classic collateral network.&#xD;
&#xD;
      Main endpoint will be comparison of a composite outcome defined as time from Moya Moya&#xD;
      diagnosis to first or recurrent stroke or bad prognosis achivement (defined by modified&#xD;
      Rankin score &gt;2)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>time from Moya Moya diagnosis to first or recurrent stroke or bad prognosis achivement</measure>
    <time_frame>1 day</time_frame>
    <description>composite endpoint of outcome defined as time from Moya Moya diagnosis to first or recurrent stroke or bad prognosis achivement (defined by modified Rankin score &gt;2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from MM diagnosis to Stroke</measure>
    <time_frame>1 day</time_frame>
    <description>Time from MM diagnosis to Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>poor prognosis or death</measure>
    <time_frame>1 day</time_frame>
    <description>poor prognosis or death (mRS&gt; 2) at the last clinical evaluation.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Moya Moya Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients &gt;=15 years of age at diagnosis of Moya Moya disease and syndrome from january 2010&#xD;
        to february 2021 at Montpellier and Martinique University Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  age &gt;=15&#xD;
&#xD;
          -  patients at diagnosis of Moya Moya disease and syndrome&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  misclassified patients&#xD;
&#xD;
          -  clinical diagnosis of MM not confirmed by angiography or MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Estelle BRITHMER, Resident</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas Gaillard, MD</last_name>
    <phone>4 67 33 74 13</phone>
    <phone_ext>33</phone_ext>
    <email>n-gaillard@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Gaillard, MD</last_name>
      <phone>4 67 33 74 13</phone>
      <phone_ext>33</phone_ext>
      <email>n-gaillard@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Estelle Brithmer</last_name>
      <phone>e-Brithmer@chu-montpellier.fr</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moya Moya syndrome</keyword>
  <keyword>Moya Moya</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moyamoya Disease</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

